Medication Comparison
Tirzepatide vs Survodutide
Tirzepatide (GLP-1/GIP) is available now and achieves ~22% weight loss. Survodutide (GLP-1/glucagon) shows ~19% in Phase 2 with a different mechanism that may be especially beneficial for liver disease (MASH). They target different secondary receptors, so the best choice may depend on the patient's full metabolic profile.
| Category | Tirzepatide | Survodutide |
|---|---|---|
| Brands | Mounjaro / Zepbound | Not yet approved (Boehringer Ingelheim) |
| Class | GLP-1/GIP dual agonist | GLP-1/Glucagon dual agonist |
| Administration | Weekly injection | Weekly injection |
| Average weight loss | ~22% | ~19% |
| Compounded cost | $150-450/mo (compounded) | Not yet available |
| Brand cost | $1,000-1,200/mo | Not yet available |
| Half-life | ~5 days | ~7 days |
| Dosing frequency | Once weekly | Once weekly |
| Key trial | SURMOUNT-1 (22.5% weight loss) | Phase 2 (up to 18.7% weight loss at 46 weeks) |
Best for Tirzepatide
Patients wanting the most effective available weight loss medication today
Best for Survodutide
Future option, especially for patients with fatty liver disease (MASH/NASH)
Tirzepatide tradeoffs
Pros
- FDA-approved and widely available
- Extensive Phase 3 data
- Proven dual mechanism
Cons
- Does not target glucagon receptor
- GIP component less studied long-term
Survodutide tradeoffs
Pros
- GLP-1 + glucagon mechanism (different from tirzepatide)
- Strong liver fat reduction
- Promising MASH/NASH data
Cons
- Not yet approved
- Slightly less weight loss than tirzepatide
- Limited long-term data
Common questions
What is survodutide?
Survodutide is a dual GLP-1/glucagon receptor agonist being developed by Boehringer Ingelheim. Unlike tirzepatide (GLP-1/GIP), it pairs GLP-1 with glucagon, which may boost energy expenditure and improve liver fat.
When will survodutide be available?
Survodutide is in Phase 3 trials for obesity and MASH (fatty liver disease). Approval could come in 2026-2027 if trials succeed.
How does survodutide differ from tirzepatide?
Both use GLP-1, but tirzepatide adds GIP (improves insulin sensitivity) while survodutide adds glucagon (increases energy expenditure and reduces liver fat). They represent different approaches to dual-receptor therapy.
Compare clinics that prescribe these medications
Use provider pages to compare clinical oversight, medication source, and pricing transparency before starting.
Related comparisons